GHRP-6 was one of the first synthetic growth hormone releasing peptides developed and remains a benchmark research compound in the GHRP class. Its defining characteristic is potent appetite stimulation via central ghrelin receptor activation, alongside a reliable and strong GH pulse.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
GHRP-6 was among the first synthetic growth hormone releasing peptides developed, and it remains one of the most studied. A 6-amino-acid peptide, it produces a strong and reliable GH pulse while also being one of the most potent appetite stimulants in the GHRP class — a direct consequence of its robust ghrelin receptor activity. This appetite-stimulating property makes GHRP-6 a useful research tool for cachexia and wasting-disease models, but a drawback for those researching fat loss or lean body composition. Understanding its distinct appetite profile compared to other GHRPs is essential for selecting the right compound for a given research objective.
Mechanism of Action
GHRP-6 is a full agonist of the ghrelin receptor (GHSR-1a) with high binding affinity. Ghrelin receptor activation in the hypothalamus and pituitary drives a two-part effect: robust GH release from pituitary somatotrophs, and simultaneous stimulation of appetite and gastric motility via CNS ghrelin signaling. GHRP-6 also inhibits somatostatin release from the hypothalamus, prolonging and amplifying the GH pulse produced by endogenous GHRH. Like GHRP-2, it produces modest elevations in cortisol and prolactin at higher doses through ACTH stimulation. Research has also demonstrated GHRP-6's ability to protect against myocardial ischemia-reperfusion injury via upregulation of anti-apoptotic proteins, making it a candidate in cardiac protection research independent of its GH-releasing effects.
Key Research
GHRP-6 was among the first synthetic GHRPs studied and was the benchmark compound in establishing the GHRP pharmacology class in the 1980s–90s. Clinical trials confirmed its ability to normalize GH secretion in GH-deficient adults and children. Its appetite-stimulating properties have been extensively documented via ghrelin receptor (GHSR-1a) activation, making it a research subject for cachexia and wasting disease models. Independent studies confirmed GHRP-6 provides cardioprotective effects against ischemia-reperfusion injury through CD36 and PI3K pathways. Its cortisol elevation profile at higher doses was established in multiple clinical crossover studies.
Standard doses are 100–300 mcg per injection, 2–3 times daily, administered subcutaneously in a fasted state. The 100 mcg dose is sufficient to produce a significant GH pulse while keeping appetite stimulation at a manageable level. The appetite surge — often described as intense, near-compulsive hunger — typically peaks 20–45 minutes post-injection and lasts 1–2 hours. For this reason, timing the injection 15–20 minutes before a planned meal is a practical strategy. As with all GHRPs, combination with a GHRH (CJC-1295 no DAC or Sermorelin) dramatically amplifies the GH pulse. Cycles of 8–12 weeks with 4-week breaks are recommended.
Mass and Appetite Research Protocol: GHRP-6 200 mcg + CJC-1295 no DAC 100 mcg 3x daily (pre-meals), 10 weeks. Cachexia/Wasting Research: GHRP-6 100–200 mcg 3x daily as a standalone or combined with IGF-1 LR3 for appetite stimulation and anabolic support. For lean body composition research, GHRP-6 is typically replaced by ipamorelin unless appetite stimulation is a desired end point.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
Intense appetite is the defining side effect of GHRP-6 and occurs in the majority of users regardless of dose. Cortisol elevation is similar to GHRP-2 — modest at 100 mcg but more pronounced at 200–300 mcg doses. Water retention, particularly in the extremities, is common during the first weeks of use. Fatigue, particularly after the GH pulse peaks, can be significant. Numbness and tingling (paresthesia) in the hands and feet are reported with higher doses or long-term use. Temporary hypoglycemia, dizziness, and flushing can occur in the first 15 minutes post-injection. Prolactin may rise modestly, particularly at higher doses.
Storage & Handling
Store lyophilized GHRP-6 powder at 2–8°C, protected from light and humidity. Stable for 12–18 months as a lyophilized powder. Reconstitute with bacteriostatic water and use reconstituted solution within 28 days when stored at 2–8°C. Do not freeze reconstituted solution. A 5 mg vial reconstituted in 2.5 mL BAC water yields a 2 mg/mL concentration.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
